Huapont Life Sciences Co.,Ltd. (SHE:002004)
China · Delayed Price · Currency is CNY 4.270
+0.070 (1.67%)
Jul 27, 2026, 3:04 PM CST
Huapont Life Sciences Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 8,424 | 9,430 | 8,918 | 9,226 | 10,098 | 14,335 | |
Market Cap Growth | -4.47% | 5.75% | -3.35% | -8.63% | -29.56% | 30.69% |
Enterprise Value | 18,500 | 20,338 | 20,417 | 19,628 | 19,449 | 22,886 |
Last Close Price | 4.27 | 4.52 | 4.10 | 4.03 | 4.22 | 5.75 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 12.32 | 13.22 | - | 30.54 | 23.29 | 21.47 |
Forward PE | - | 23.63 | 23.63 | 23.63 | 23.63 | 23.63 |
PS Ratio | 0.73 | 0.82 | 0.77 | 0.80 | 0.76 | 1.15 |
PB Ratio | 0.49 | 0.56 | 0.58 | 0.56 | 0.61 | 0.91 |
P/TBV Ratio | 1.22 | 1.41 | 1.54 | 1.60 | 1.83 | 2.90 |
P/FCF Ratio | 4.96 | 6.47 | 13.33 | 30.22 | 7.91 | 1086.87 |
P/OCF Ratio | 3.71 | 4.50 | 5.49 | 5.81 | 4.19 | 11.29 |
PEG Ratio | - | 23.63 | 23.63 | 23.63 | 23.63 | 23.63 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.61 | 1.77 | 1.75 | 1.69 | 1.47 | 1.84 |
EV/EBITDA Ratio | 7.64 | 8.71 | 10.19 | 9.07 | 7.35 | 10.40 |
EV/EBIT Ratio | 13.72 | 15.44 | 19.11 | 15.02 | 10.37 | 15.42 |
EV/FCF Ratio | 10.90 | 13.95 | 30.52 | 64.28 | 15.23 | 1735.25 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.46 | 0.43 | 0.57 | 0.52 | 0.49 | 0.57 |
Debt / EBITDA Ratio | 3.32 | 3.07 | 4.36 | 3.92 | 3.01 | 4.02 |
Debt / FCF Ratio | 4.73 | 4.99 | 13.29 | 28.25 | 6.30 | 679.94 |
Net Debt / Equity Ratio | 0.18 | 0.09 | 0.22 | 0.18 | 0.14 | 0.19 |
Net Debt / EBITDA Ratio | 1.32 | 0.64 | 1.69 | 1.39 | 0.89 | 1.34 |
Net Debt / FCF Ratio | 1.85 | 1.02 | 5.07 | 9.88 | 1.85 | 223.34 |
Asset Turnover | 0.39 | 0.39 | 0.39 | 0.38 | 0.44 | 0.43 |
Inventory Turnover | 3.53 | 3.44 | 3.18 | 2.77 | 3.23 | 3.57 |
Quick Ratio | 0.94 | 0.99 | 0.83 | 0.78 | 0.77 | 0.82 |
Current Ratio | 1.40 | 1.26 | 1.08 | 1.07 | 1.04 | 1.08 |
Return on Equity (ROE) | 5.33% | 5.43% | -2.14% | 4.09% | 6.96% | 6.14% |
Return on Assets (ROA) | 2.82% | 2.82% | 2.22% | 2.69% | 3.90% | 3.18% |
Return on Invested Capital (ROIC) | 5.71% | 5.88% | 5.56% | 5.15% | 6.92% | 5.73% |
Return on Capital Employed (ROCE) | 6.40% | 6.60% | 5.60% | 6.50% | 9.90% | 8.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 8.12% | 7.56% | -3.35% | 3.28% | 4.29% | 4.66% |
FCF Yield | 20.15% | 15.46% | 7.50% | 3.31% | 12.64% | 0.09% |
Dividend Yield | 11.90% | 9.95% | - | 5.46% | 5.21% | 3.82% |
Payout Ratio | 95.82% | 93.73% | - | 250.32% | 197.10% | 128.69% |
Buyback Yield / Dilution | 0.05% | 0.10% | 0.25% | 0.02% | -0.02% | -0.25% |
Total Shareholder Return | 11.95% | 10.05% | 0.25% | 5.48% | 5.19% | 3.58% |